Covid-19 Discussions

To help break down the complex biotechnological landscape surrounding Covid-19 and our maps, we offer periodic, interactive, webinar-style discussions led by members of our team. We welcome all those involved in biotechnology or public health, including scientific innovators, policymakers, members of the media, academics, medical professionals, and representatives of non-profits or NGOs.

Upcoming Live Covid-19 Discussion:


Our next live Covid-19 Discussion is scheduled for December 2, 2020 - 4:00 PM ET

Register Now


Previously Recorded Covid-19 Discussions:

DISCUSSION 15
November 18, 2020
Positive interim data in Moderna’s Ph3 vaccine trial, how antibody titers diminish over time, aspirin being tested in a large Ph3 randomized control trial in hospitalized patients, Ilaris (an anti-IL-1b monoclonal antibody) fails in a late stage study, FDA approves an “at home” COVID-19 test.

DISCUSSION 14
November 11, 2020
Positive interim data from Pfizer/BioNTech’s Ph3 vaccine trial showed >90% efficacy, the risk of novel SARS-CoV2 variants, and update on the EUA for Lilly’s antibody.
Watch Video

DISCUSSION 13
November 4, 2020
Regeneron antibody cocktail clinical update, case study on how Taiwan has gone 200 days without a new local infection, FDA panel presents data that some COVID-19 tests are not very good, poll of Americans regarding vaccine hesitancy, monitoring vaccine safety after approval.
Watch Video

DISCUSSION 12
October 27, 2020
Discussion on the Remdesivir approval, Vaccines Adcom, and risk of COVID-19 transmission on airplanes.
Watch Video

DISCUSSION 11
October 21, 2020
Discussion of results from the WHO’s trial of Remdesivir and tips on using diagnostics to help plan holiday get-togethers.
Watch Video

DISCUSSION 10
October 14, 2020
Exploration of why people are still getting sick with infectious diseases despite self-isolating, details on the J&J vaccine trial hold, and a discussion of the FDA’s vaccine EUA guidelines.
Watch Video

DISCUSSION 9
October 7, 2020
Discussion of the newly released data for Regeneron’s mAb cocktail and also on how the White House is dealing with a COVID-19 outbreak.
Watch Video

DISCUSSION 8
September 29, 2020
Case studies of how diagnostics can help reduce the spread of COVID-19 and contextualizing the recent J&J vaccine data.
Watch Video

DISCUSSION 7
September 22, 2020
Covid Tx map update, a case for multiplexed trials, and home testing.
Watch Video

DISCUSSION 6
September 16, 2020
Discussion of when a COVID-19 vaccine could become available and how much it might cost.
Watch Video

DISCUSSION 5
September 10, 2020
Comparing tolerability for vaccine candidates; possibilities of a combined flu/COVID vaccine.
Watch Video

DISCUSSION 4
September 1, 2020
Emergency use authorization and how it may impact vaccine development; Follow up on human convalescent serum and the broadening of Remdesivir’s label; Approval of Abbot’s diagnostic test; Concerns around herd immunity and evaluating Sweden’s approach.
Watch Video

DISCUSSION 3
August 26, 2020
What data did human convalescent serum show for approval, and what does this mean for companies developing antibodies; What would accelerated approval for a vaccine mean for opening up the country, and the development of other vaccines; Possibilities of reinfection.
Watch Video

DISCUSSION 2
August, 19 2020
Walkthrough of comparative vaccine data for the major vaccines in development; Discussion of immune modulators as COVID therapy.
Watch Video

DISCUSSION 1
August 12, 2020
Walkthroughs by the RA team on COVID Vaccines, Therapeutics, and Diagnostics, highlighting the most interesting programs in development.
Watch Video